Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LSS | P48449 | 3/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21101593 | 0.92 | KDM4E (0.44) | LSSHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL21102457 | 0.81 | KDM4E (0.38) | LSSHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL14575869 | 0.79 | HTR2A (0.46) | LSSHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL15171151 | 0.79 | LSS (0.40) | LSSHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL14575871 | 0.79 | HTR2A (0.46) | LSSHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL21101599 | 0.79 | SLC6A2 (0.34) | SIGMAR1 | |
| SCHEMBL24541657 | 0.78 | LSS (0.38) | LSSHTR2AHTR2CHTR2BSIGMAR1 | |
| Hydrochloric Acid SCHEMBL15136222 | 0.78 | HTR2A (0.45) | LSSHTR2AHTR2CHTR2BSIGMAR1 | |
| Hydrochloric Acid SCHEMBL15136221 | 0.78 | HTR2A (0.45) | LSSHTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL14617850 | 0.78 | HTR2A (0.39) | LSSHTR2AHTR2CHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10323037-B2 | Aminopyridazinone compounds as protein kinase inhibitors | SSB, MAPKAPK5, BCL9 | LSS 3394/4885HTR2A 3926/4885HTR2C 3942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.